News Release

The U.S. Food and Drug Administration (FDA) should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says the IOM's report Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease.